Analysts’ Weekly Ratings Updates for GE HealthCare Technologies (GEHC)

Several analysts have recently updated their ratings and price targets for GE HealthCare Technologies (NASDAQ: GEHC):

• 4/11/2024 – GE HealthCare Technologies had its price target raised by analysts at Mizuho from $96.00 to $110.00. They now have a “buy” rating on the stock.
• 4/4/2024 – GE HealthCare Technologies had its price target raised by analysts at Evercore ISI from $93.00 to $100.00. They now have an “outperform” rating on the stock.
• 4/3/2024 – GE HealthCare Technologies had its price target raised by analysts at Citigroup Inc. from $88.00 to $103.00. They now have a “buy” rating on the stock.
• 4/1/2024 – GE HealthCare Technologies had its price target raised by analysts at Argus from $80.00 to $110.00. They now have a “buy” rating on the stock.

GE HealthCare Technologies Trading Down 0.3 %

Shares of GE HealthCare Technologies stock opened at $85.88 on Wednesday. The company’s fifty day simple moving average is $88.55 and its 200-day simple moving average is $77.60. The company has a market cap of $39.19 billion, a price-to-earnings ratio of 28.44, a PEG ratio of 3.00 and a beta of 0.95. The company has a current ratio of 1.05, a quick ratio of 0.83 and a debt-to-equity ratio of 1.18. GE HealthCare Technologies Inc. has a 1 year low of $62.35 and a 1 year high of $94.50.

GE HealthCare Technologies (NASDAQ:GEHC) last issued its earnings results on Tuesday, February 6th. The company reported $1.18 EPS for the quarter, topping the consensus estimate of $1.07 by $0.11. The firm had revenue of $5.20 billion during the quarter, compared to analysts’ expectations of $5.09 billion. GE HealthCare Technologies had a return on equity of 25.58% and a net margin of 8.02%. GE HealthCare Technologies’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same period last year, the business earned $1.31 earnings per share. As a group, sell-side analysts expect that GE HealthCare Technologies Inc. will post 4.3 EPS for the current year.

GE HealthCare Technologies Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 15th. Shareholders of record on Friday, April 19th will be issued a dividend of $0.03 per share. The ex-dividend date of this dividend is Thursday, April 18th. This represents a $0.12 dividend on an annualized basis and a dividend yield of 0.14%. GE HealthCare Technologies’s payout ratio is presently 3.97%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Wynn Capital LLC increased its stake in shares of GE HealthCare Technologies by 4.1% in the first quarter. Wynn Capital LLC now owns 3,125 shares of the company’s stock valued at $284,000 after buying an additional 122 shares in the last quarter. Fiduciary Trust Co increased its stake in shares of GE HealthCare Technologies by 1.8% in the fourth quarter. Fiduciary Trust Co now owns 7,696 shares of the company’s stock valued at $595,000 after buying an additional 133 shares in the last quarter. Janney Capital Management LLC increased its stake in shares of GE HealthCare Technologies by 4.7% in the fourth quarter. Janney Capital Management LLC now owns 3,289 shares of the company’s stock valued at $254,000 after buying an additional 149 shares in the last quarter. American National Bank increased its stake in shares of GE HealthCare Technologies by 25.2% in the fourth quarter. American National Bank now owns 750 shares of the company’s stock valued at $58,000 after buying an additional 151 shares in the last quarter. Finally, Armstrong Henry H Associates Inc. increased its stake in shares of GE HealthCare Technologies by 3.9% in the third quarter. Armstrong Henry H Associates Inc. now owns 4,105 shares of the company’s stock valued at $279,000 after buying an additional 153 shares in the last quarter. 82.06% of the stock is owned by institutional investors.

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.